We Are Rats; If Pharma Could Be Brave … And Other Bullseye POVs You Won’t Hear at Other Events
MedCity News’ new event for healthcare investors and corporate business development leads — Bullseye —…
We Are Rats; If Pharma Could Be Brave … And Other Bullseye POVs You Won’t Hear at Other Events
MedCity News’ new event for healthcare investors and corporate business development leads — Bullseye — hit the mark when it comes to provocative and thoughtful commentary. Here’s what was said in panels throughout the day. The post We Are Rats; If Pharma Could Be Brave … And Other Bullseye POVs You Won’t Hear at Other…
The same 10mg Zepbound costs $449 or $699
By JOHN SAMARAS Eli Lilly sells a month of 10mg Zepbound for $449 through LillyDirect, its own pharmacy. That price holds only if you refill within 45 days of your last fill. Refill on day 46 and the same box is $699. The $250 is a late fee. Here are the two ways to buy…
Why Hims & Hers Is Embroiled in Yet Another Controversy, This Time with the FTC
The FTC and the states of Utah and California sued Hims & Hers, alleging it improperly shared consumers’ health information and misled customers about billing, subscriptions and cancellations. The post Why Hims & Hers Is Embroiled in Yet Another Controversy, This Time with the FTC appeared first on MedCity News.
J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.85 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases. The post J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy appeared first on MedCity News.
Health and Health Care Experiences of Uninsured Immigrants
This brief provides data on health and health care experiences of uninsured immigrant adults based on a KFF survey of immigrant adults ages 18 and older conducted in partnership with The New York Times in Fall 2025. The data provide insight into how the projected coverage losses under the 2025 reconciliation law may impact health…
More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients
Interdisciplinary coordination between nephrologists, primary care providers, pharmacists, dieticians, and everyone who interacts with patients is essential to ensure patient education, improve adherence, and reduce medication errors. The post More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients appeared first on MedCity News.
The Code Gets You Paid — The Variant Gets You Treated
The between a code that satisfies a payer and the information a physician needs to treat a person, is what nearly every healthcare AI tool is racing past. As we push these systems toward precision medicine and genomics, that gap stops being an annoyance and becomes a patient safety issue. The post The Code Gets…
Moving Beyond Reactive Healthcare: 5 Traits of Successful Healthcare Organizations
[Sponsored] A new whitepaper by League highlights examples from collaborations with Baptist Health. The post Moving Beyond Reactive Healthcare: 5 Traits of Successful Healthcare Organizations appeared first on MedCity News.
KFF Health Tracking Poll: Mifepristone and the Midterms
Amid an ongoing FDA re-review of mifepristone, awareness of the safety and prevalence of the abortion pill remains limited. This KFF poll also finds that the voters who say abortion policy is an important issue for 2026 midterm candidates to discuss are disproportionately Democrats.
Medicaid Insurers’ Contracts on the Line in Tight Governor’s Race
One of America’s most competitive gubernatorial races could settle a heated argument over whether private insurance companies should run Medicaid. The race is in Iowa, whose Medicaid program has been plagued with controversy since 2016, when the state hired national insurance companies to manage billions of dollars’ worth of benefits. That shift was made by…
